GlassScriptPhysician profile
Kashiff Ariff
NPI 1770271181
$1,349.49
in general payments reported to CMS, 2019-2025
15 companies · $445 in 2025
The $445 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $144 · 2024: $760 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $385.69 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $354.83 | 2023-2024 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $236.17 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $58.44 | 2024 | Hyqvia |
| Biogen, INC. | $50.94 | 2024 | Tysabri |
| Otsuka America Pharmaceutical, INC. | $42.01 | 2025 | Rexulti |
| Csl Behring | $32.92 | 2025 | Hizentra |
| Acadia Pharmaceuticals INC | $31.55 | 2025 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $27.74 | 2024 | |
| Lundbeck LLC | $27.49 | 2025 | Vyepti |
| Genentech USA, INC. | $22.99 | 2025 | Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $22.09 | 2025 | Ponvory |
| E.R. Squibb & Sons, L.L.C. | $22.00 | 2024 | Zeposia |
| Medtronic, INC. | $19.76 | 2025 | Osteocool Rf Ablation System |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashiff Ariff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.